Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Diseases

Background:

• Obesity and diabetes are global health crises with increasing prevalence and mortality.
• Current pharmacotherapies for weight management and glycemic control often show limited efficacy or safety concerns.
• Historical treatments have included thyroid extracts, amphetamines, and hormones, with modest results.

Purpose of the Study:

• To review historical pharmacological approaches for treating obesity and glucose intolerance.
• To highlight the development and potential of unimolecular dual agonists in obesity pharmacology.
• To explain how past research paved the way for novel polypharmacological strategies.

Main Methods:

• Literature review of historical and recent pharmacological interventions for obesity and diabetes.
• Analysis of drug efficacy and safety data from preclinical and clinical studies.
• Focus on the evolution of single-molecule therapies targeting multiple receptors.

Main Results:

• Many early pharmacotherapies demonstrated limited efficacy, with placebo-subtracted weight loss typically below 10%.
• The development of unimolecular dual agonists targeting glucagon and glucagon-like peptide 1 receptors represents a significant advancement.
• These novel agents combine anorectic, glycemic, and thermogenic effects for enhanced potency and sustained action.

Conclusions:

• Unimolecular polypharmacology, exemplified by dual glucagon/GLP-1 agonists, offers a promising future for obesity and diabetes treatment.
• Knowledge gained from historical pharmacotherapies has been crucial in developing these advanced therapeutic strategies.
• Further research into these novel agents is expected to lead to more effective treatments for metabolic disorders.